Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported): January 12, 2007
Calypte
Biomedical Corporation
(Exact
name of Company as specified in its charter)
Delaware
|
000-20985
|
06-1226727
|
(State
or Other
Jurisdiction)
|
(Commission
File
Number)
|
(I.R.S.
Employer
Identification)
|
of
Incorporation)
|
|
|
5
Centerpointe Drive, Suite 400, Lake Oswego, OR 97035
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (971)
204-0282
N/A
(Former
name or former address, if changed since last report)
o Written
communication pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
40.13e-4(c))
Item
5.02 Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers.
(b) On
January 12, 2007, Theodore R. Gwin ceased his employment as Chief Financial
Officer of Calypte Biomedical Corporation to pursue other interests. Roger
I.
Gale, Chief Executive Officer, will assume the role of Chief Financial Officer
on an interim basis until a successor to Mr. Gwin is named.
SIGNATURES
Pursuant
to the requirement of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: |
Lake Oswego, Oregon |
|
January 19,
2007 |
|
|
|
|
Calypte
Biomedical
Corporation |
|
|
|
|
By: |
/s/ Roger
I.
Gale |
|
Roger
I Gale |
|
Chief
Executive Officer |